CYP2C19‐Guided Voriconazole Therapy: A Precision Medicine Approach to Mitigate Adverse Effects in Japanese Patients
ABSTRACT Voriconazole (VRCZ) is a triazole antifungal agent with a broad antifungal spectrum. It is metabolized by hepatic cytochrome P450 (CYP) isozyme CYP2C19, whose genetic polymorphism causes significant variability in drug efficacy and safety. Poor metabolizer alleles of CYP2C19 are more common...
Saved in:
| Main Authors: | Yoshiki Katada, Daiki Hira, Keisuke Umemura, Yurie Katsube, Hiroki Ishimura, Yusuke Kojima, Machiko Hirai, Moto Kajiwara, Mitsuhiro Sugimoto, Hiroki Endo, Junru Cao, Saki Ohta, Kinuka Kotani, Sakiko Hatazoe, Masahiro Tsuda, Shunsaku Nakagawa, Koh Shinohara, Yasuhiro Tsuchido, Miki Nagao, Tomohiro Terada |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Clinical and Translational Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/cts.70317 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A case of pulmonary histoplasmosis treated with voriconazole
by: Congyi Xie, et al.
Published: (2022-03-01) -
Risk factors for voriconazole-associated hepatotoxicity in patients with liver dysfunction: a retrospective nested case–control study
by: Jing Ren, et al.
Published: (2025-08-01) -
Invasive aspergillosis in an immunocompetent patient: A retrospective case report and review of the literature
by: Xiaobing Zhang, et al.
Published: (2024-11-01) -
Recurrent Pulmonary Infection Caused by Schizophyllum commune: A Case Report and Management of Inflammation
by: Shuai Ren, et al.
Published: (2025-07-01) -
Modulating the Antifungal Activity of Antimycotic Drugs with Farnesol
by: N. P. Sachivkina, et al.
Published: (2021-11-01)